WORLD PEPTIDEFOUNDATION

Where is CJC-1295 being studied?

Find registered human studies, phases, products, recruitment status and reported research locations around the world. Registry search matches are separate from this profile’s reviewed evidence.

Find studies for CJC-1295 →Worldwide registry directory
Search this profile’s alternative names

Check the intervention identity in each registry record; aliases and combination products can produce broader matches.

Scientific intelligence record

Experience 2.0

Long-acting GHRH analog

CJC-1295

Also known as: CJC1295, CJC-1295 DAC, Drug Affinity Complex GRF

CJC-1295 is a modified growth-hormone-releasing hormone analog designed to resist enzymatic degradation and, in its drug-affinity-complex form, bind circulating albumin. Early studies show prolonged stimulation of growth hormone and IGF-1, but biomarker elevation is not equivalent to demonstrated clinical benefit.

Record status

Traceability partial

Last meaningful update: 9/8/2026

Evidence searched through:
Not recorded
Assessment updated:
9/8/2026
Documented human review:
No documented human review recorded
Automated scientific assessment:
9/8/2026
AI source check:
None recorded

Published source links and profile text pass separate gates. Only a documented human review is labelled as human review; an automated scientific assessment applies deterministic checks, and an AI source check confirms only that a source exists and matches its identifiers. A source count alone does not establish a review.

Evidence coverage has three distinct layers. The corpus count is a transparent screening inventory, the featured set contains study-level tiering and interpretation, and the published-source count contains records promoted through the institutional publication workflow. Source validation, editorial publication, and scientific appraisal are separate decisions; these numbers must not be merged.

Ranked research corpus

36

Categorized publications with provisional ranking; scientific review remains separate.

Featured tiered studies

0

Cornerstone publications with study-level interpretation, limitations, and tier disclosure.

Research domains

4

Clinical and scientific questions synthesized independently across the evidence atlas.

Published source records

25

Database records promoted through the governed publication workflow—not the corpus total.

Corpus generated 2026-09-18. Counts remain separately labeled so screening is not represented as completed review.

Human experience · separate evidence stream

No community pattern is displayed yet

Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.

Observation is valuable human context. It is not evidence of causation, efficacy, or safety.

Public display gate

n ≥ 20 eligible observations

Exact progress remains private before the threshold.

Contribute an observationArchive details

Intelligence snapshot

The state of the record

A compact view of what is represented, what remains unresolved, and how completely the record can be traced.

Ranked research corpus

36

Categorized screening records; proposed rankings remain pending human appraisal.

Featured tiered studies

0

Cornerstone studies with published study-level interpretation and tier disclosure.

Research domains

4

Independent evidence dossiers covering the major research questions.

Published source records

25

Source records published through the governed workflow; this count does not certify scientific conclusions.

Contradictions

0

Conflicting evidence relationships that remain visible.

Research gaps

1

Questions the current record identifies as unresolved.

Connected media

0

Media records explicitly linked to this scientific record.

What we know

Evidence, claims, and boundaries

The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.

Reconciled domain conclusions

4 published domain syntheses connected to 0 featured studies

CJC-1295 no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded synthesis, confidence level, evidence context, limitations, geographic applicability, regulatory interpretation, and research gaps. Publication of these syntheses is separate from the scientific review status shown above.

Inspect the reconciled evidence atlas
Inspect the published evidence record25 governed records · titles, provenance, and original-source linksOpen records ↓
2006Phase 1–2 human evidence
Evidence strength B · 74/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
68/100
Directness
88/100
Population relevance
78/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

OBJECTIVE: The objective of this study was to examine the pharmacokinetic profile, pharmacodynamic effects, and safety of CJC-1295, a long-acting GHRH analog. DESIGN: The study design was two randomized, placebo-controlled, double-blind, …

Authors
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA.
Source
peer_reviewed_research
DOI
10.1210/jc.2005-1536
PubMed
16352683
Open original source
2026Phase 1–2 human evidence
Evidence strength B · 74/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
68/100
Directness
88/100
Population relevance
78/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 (anti-obesity drug 9604), BPC-157 (body protection compound 157), CJC-1295 …

Authors
Mendias CL, Awan TM.
Source
peer_reviewed_research
DOI
10.1007/s40279-026-02437-0
PubMed
41966639
Open original source
2016Observational human evidence
Evidence strength B · 70/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
56/100
Directness
88/100
Population relevance
72/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.

The target analytes included Geref (Sermorelin), CJC-1293, CJC-1295, and Egrifta (Tesamorelin) as well as two metabolites of Geref and CJC-1293, which were captured from plasma samples using a polyclonal GHRH antibody in concert with protein A/G monolithic MSIA D.A …

Authors
Knoop A, Thomas A, Fichant E, Delahaut P, Schänzer W, Thevis M.
Source
peer_reviewed_research
DOI
10.1007/s00216-016-9377-3
PubMed
26879649
Open original source
2006Animal research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
46/100
Directness
88/100
Population relevance
25/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.

We report the effects of CJC-1295 administration in GHRHKO animals. Three groups of 1-wk-old GHRHKO mice were treated for 5 wk with 2 microg of CJC-1295 at intervals of 24, 48, and 72 h. ...These findings demonstrate that treatment with once-daily admi …

Authors
Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R.
Source
peer_reviewed_research
DOI
10.1152/ajpendo.00201.2006
PubMed
16822960
Open original source
2022Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Early detection of cannabinoids in biological samples based on their affinity interaction with the growth hormone secretagogue receptor.

The affinity profiles of CBD and carboxy-THC are significantly different from the profiles of synthetic GHR mimetics such as CJC-1295 or [D-Arg(1)-D-Phe(5)-D-Trp(7,9)-Leu(11)]-Substance P peptides, which are the most common interferents; the cannabinoids promoted th …

Authors
Danila GM, Puiu M, Zamfir LG, Bala C.
Source
peer_reviewed_research
DOI
10.1016/j.talanta.2021.122905
PubMed
34736642
Open original source
2023Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.

The present developed and validated method for some GHRHs (tesamorelin, CJC-1295, sermorelin (GRF 1-29), sermorelin (3-29)-NH(2), somatorelin) is based on the triple quadrupole UHPLC/MS-MS method with solid phase extraction (SPE) with weak cation exchange and is abl …

Authors
Cristea CD, Radu M, Toboc A, Stan C, David V.
Source
peer_reviewed_research
DOI
10.1016/j.ab.2023.115336
PubMed
37806509
Open original source
2006Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.

OBJECTIVE: Our objective was to assess GH pulsatility after a single injection of CJC-1295 and determine which GH secretion parameters correlated to the increase in IGF-I production. METHODS: GH pulsatility was assessed by 20-min blood sampling during an overnight 1 …

Authors
Ionescu M, Frohman LA.
Source
peer_reviewed_research
DOI
10.1210/jc.2006-1702
PubMed
17018654
Open original source
2026Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.

The present study aimed to develop a robust nano-LC quadrupole/orbitrap mass spectrometry (nano-LC-Q/Orbitrap MS) method for both screening and confirmation analyses of GHRH and its synthetic analogs (sermorelin/CJC-1293, tesamorelin, and CJC-1295) and the primary m …

Authors
Uçaktürk E, Nemutlu E.
Source
peer_reviewed_research
DOI
10.1016/j.jpba.2025.117207
PubMed
41138283
Open original source
2016Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

The study of doping market: How to produce intelligence from Internet forums.

A temporal analysis illustrates the stability of the most popular products as well as the emergence of new products such as peptides (e.g. CJC-1295). 327 suppliers were detected, mostly with dedicated websites or direct sales by e-mail as selling methods. ...

Authors
Pineau T, Schopfer A, Grossrieder L, Broséus J, Esseiva P, Rossy Q.
Source
peer_reviewed_research
DOI
10.1016/j.forsciint.2016.09.017
PubMed
27710891
Open original source
2019Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.

CJC-1295 is a peptide-based drug that stimulates the production of growth hormone (GH) from the pituitary gland. ...Previously we described a screening procedure for the detection of CJC-1295 in equine plasma using an immuno-PCR assay. Here we demonstr …

Authors
Timms M, Ganio K, Steel R.
Source
peer_reviewed_research
DOI
10.1002/dta.2599
PubMed
30938069
Open original source
2016Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.

METHODS: A systematic Internet search was conducted using variation of the term "CJC-1295"; and combined with "forum." Ninety-six hits related to bodybuilding websites where CJC-1295 was mentioned. ...These were searched internally for reference to …

Authors
Van Hout MC, Hearne E.
Source
peer_reviewed_research
DOI
10.3109/10826084.2015.1082595
PubMed
26771670
Open original source
2024Laboratory research
Evidence strength D · 49/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
45/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.

With urine samples representing still the most frequently collected doping control specimens, efficient extraction of peptidic analytes from this matrix was a major goal of this method, as demonstrated for the included compounds such as insulins (human, lispro, aspart, glulisine, …

Authors
Thomas A, Walpurgis K, Thevis M.
Source
peer_reviewed_research
DOI
10.1002/jms.4996
PubMed
38197510
Open original source
2022Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Probing for peptidic drugs (2-10 kDa) in doping control blood samples.

Co-extraction and analysis of several different peptides such as insulins (human, lispro, aspart, glulisine, tresiba, detemir, glargine, bovine insulin and porcine insulin), growth hormone releasing hormones (sermorelin, CJC-1295 and tesamorelin), insulin-like growt …

Authors
Thomas A, Thilmany S, Hofmann A, Thevis M.
Source
peer_reviewed_research
DOI
10.1002/ansa.202200027
PubMed
38716080
Open original source
2026Laboratory research
Evidence strength D · 49/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
45/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

This peer-reviewed source examines Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

Authors
Renke G, Chinellato L.
Source
peer_reviewed_research
DOI
10.3390/ijms27093890
PubMed
42123471
Open original source
2026Laboratory research
Evidence strength C · 63/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
72/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.

Regenerative peptides (e.g., body protection compound-157 and thymosin derivatives) and growth hormone axis secretagogues (e.g., CJC-1295, ipamorelin, and tesamorelin) remain investigational, with uncertain safety profiles, product quality concerns, and widespread a …

Authors
Villegas Meza AD, Nocek M, Mitchell BC, Lizarraga M, DeFoor MT, Ruzbarsky JJ, Huard J, Philippon MJ.
Source
peer_reviewed_research
DOI
10.2106/JBJS.RVW.26.00027
PubMed
42160466
Open original source
2026Laboratory research
Evidence strength C · 63/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
72/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Peptide Supplements and Their Therapeutic Applications in Sports Medicine.

PURPOSE: To summarize existing peer-reviewed data on 6 emerging peptides (BPC-157, thymosin beta-4 or TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu [copper peptide]) for musculoskeletal recovery and enhancement in animal and human models. ...METHODS: Three indepe …

Authors
Tewari K, Liu TP, Im C, Hamad C, Petrigliano F, Cheung EC, Kremen TJ Jr.
Source
peer_reviewed_research
DOI
10.1177/03635465261464420
PubMed
42578445
Open original source
2009Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.

Serum GH and IGF-1 levels have been shown to increase with administration of GHRH or CJC-1295, a long-acting GHRH analog. DESIGN: Sera from 11 healthy young adult men before and one week after CJC-1295 injection were analyze …

Authors
Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ.
Source
peer_reviewed_research
DOI
10.1016/j.ghir.2009.03.001
PubMed
19386527
Open original source
2021Laboratory research
Evidence strength C · 58/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
18/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Advances in the detection of growth hormone releasing hormone synthetic analogs.

This study investigates the in vitro metabolism and detection of four of the larger GHRH synthetic analogs (sermorelin, tesamorelin, CJC-1295, and CJC-1295 with drug affinity complex) in fortified urine. Nineteen major in vitro metabolites were identif …

Authors
Memdouh S, Gavrilović I, Ng K, Cowan D, Abbate V.
Source
peer_reviewed_research
DOI
10.1002/dta.3183
PubMed
34665524
Open original source
2026Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation, whereas growth hormone secretagogues like ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD-9604 activ …

Authors
Rahman OF, Lee SJ, Seeds WA.
Source
peer_reviewed_research
DOI
10.5435/JAAOSGlobal-D-25-00236
PubMed
41490200
Open original source
2026Laboratory research
Evidence strength C · 63/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
72/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.

Marketed as more selective and ostensibly safer alternatives, peptides-including growth hormone secretagogues (e.g., Ipamorelin), growth hormone-releasing hormone analogues (e.g., CJC-1295, Sermorelin), and synthetic fragments (e.g., Frag 176-191, KPV)-are promoted …

Authors
Coutinho LFD, DE Oliveira Neves LF, Camilo RP.
Source
peer_reviewed_research
DOI
10.23736/S0022-4707.26.17773-1
PubMed
41880199
Open original source
2020Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.

Growth hormone-releasing hormone and its analogues sermorelin, tesamorelin and CJC-1295 are included in the prohibited list of the World Antidoping Agency. These target peptides are found at very low concentrations in urine (at the pg/mL level). ...

Authors
Pont L, Alechaga É, Terrero A, Monfort N, Ventura R.
Source
peer_reviewed_research
DOI
10.1016/j.chroma.2020.461548
PubMed
32971474
Open original source
2026Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

Key peptides evaluated included BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu. RESULTS: BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials. ...TB-4 and its derivativ …

Authors
Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE.
Source
peer_reviewed_research
DOI
10.1177/03635465251357593
PubMed
41476424
Open original source
2022Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.

This work presents an ultrafiltration-based, validated method for the screening and confirmation of prohibited growth hormone-releasing hormone (GHRH) analogues (sermorelin/CJC-1293, sermorelin metabolite, CJC-1295 and tesamorelin) in urine by nanoLC-HRMS/MS. Sample …

Authors
Coppieters G, Deventer K, Polet M, Van Eenoo P, Judák P.
Source
peer_reviewed_research
DOI
10.1016/j.jpba.2022.114726
PubMed
35298973
Open original source
2015Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS.

Such peptides have been used to manipulate several potential performance-enhancing processes in the athlete's body and include for example growth hormone releasing hormones (sermorelin, CJC-1293, CJC-1295, tesamorelin), synthetic/animal insulins (lispro, aspart, glu …

Authors
Thomas A, Walpurgis K, Tretzel L, Brinkkötter P, Fichant E, Delahaut P, Schänzer W, Thevis M.
Source
peer_reviewed_research
DOI
10.1002/dta.1868
PubMed
26382721
Open original source
2019Laboratory research
Evidence strength C · 60/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Source authority
78/100
Study design and bias control
42/100
Directness
88/100
Population relevance
30/100
Reporting quality
68/100
Replication
45/100

Automated structured-metadata baseline; full-text risk-of-bias review may revise this rating.

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.

CJC-1295 is a 30 amino acid peptide-based drug that stimulates the release of growth hormone (GH) from the pituitary gland. ...Using a pair of monoclonal antibodies raised against the CJC-1295 peptide, we present an immuno-polymerase chain reaction (I- …

Authors
Timms M, Ganio K, Forbes G, Bailey S, Steel R.
Source
peer_reviewed_research
DOI
10.1002/dta.2554
PubMed
30489688
Open original source

Scientific context

Chemistry and represented biological context

Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.

Open chemistry and biological context ↓
Chemical identity

Molecular and structural record

Structured record

The chemistry record exists, but no displayable molecular fields have been entered yet.

Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.

Explore further

Continue through the research system

Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.

Research discovery

Compare peptides

Examine represented peptide records side by side.

Evidence system

Explore how scientific evidence is represented and reviewed.

Research hub

Enter the broader research and intelligence environment.

Methodology

Review project methods, boundaries, and interpretation rules.

Research

How the scientific record is developing

Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.

Research chronology

  1. 2006 · study · Temporal status not established

    Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

    peer_reviewed_research

  2. 2006 · study · Temporal status not established

    Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.

    peer_reviewed_research

  3. 2006 · study · Temporal status not established

    Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.

    peer_reviewed_research

  4. 2009 · study · Temporal status not established

    Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.

    peer_reviewed_research

  5. 2015 · study · Temporal status not established

    Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS.

    peer_reviewed_research

  6. 2016 · study · Temporal status not established

    Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.

    peer_reviewed_research

  7. 2016 · study · Temporal status not established

    The study of doping market: How to produce intelligence from Internet forums.

    peer_reviewed_research

  8. 2016 · study · Temporal status not established

    Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.

    peer_reviewed_research

  9. 2019 · study · Temporal status not established

    A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.

    peer_reviewed_research

  10. 2019 · study · Temporal status not established

    An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.

    peer_reviewed_research

  11. 2020 · study · Temporal status not established

    Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.

    peer_reviewed_research

  12. 2021 · study · Temporal status not established

    Advances in the detection of growth hormone releasing hormone synthetic analogs.

    peer_reviewed_research

  13. 2022 · study · Temporal status not established

    Early detection of cannabinoids in biological samples based on their affinity interaction with the growth hormone secretagogue receptor.

    peer_reviewed_research

  14. 2022 · study · Temporal status not established

    Probing for peptidic drugs (2-10 kDa) in doping control blood samples.

    peer_reviewed_research

  15. 2022 · study · Temporal status not established

    An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.

    peer_reviewed_research

  16. 2023 · study · Temporal status not established

    Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.

    peer_reviewed_research

  17. 2024 · study · Temporal status not established

    Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.

    peer_reviewed_research

  18. 2026 · study · Temporal status not established

    Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

    peer_reviewed_research

  19. 2026 · study · Temporal status not established

    Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.

    peer_reviewed_research

  20. 2026 · study · Temporal status not established

    Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

    peer_reviewed_research

  21. 2026 · study · Temporal status not established

    Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.

    peer_reviewed_research

  22. 2026 · study · Temporal status not established

    Peptide Supplements and Their Therapeutic Applications in Sports Medicine.

    peer_reviewed_research

  23. 2026 · study · Temporal status not established

    Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

    peer_reviewed_research

  24. 2026 · study · Temporal status not established

    A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.

    peer_reviewed_research

  25. 2026 · study · Temporal status not established

    Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

    peer_reviewed_research

  26. 2026 · regulatory · Temporal status not established

    Regulatory review: not_approved

    European Union (EMA)

  27. 2026 · regulatory · Temporal status not established

    Regulatory review: not_approved

    United States (FDA)

The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.

What still needs investigation

Claim traceability

No institutional claim record is currently represented for this peptide.

Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.

Researchers represented in the evidence record12 bibliographic identities · open to inspect

These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.

Thevis M.

4 represented evidence records

Years represented: 2015, 2016, 2022, 2024

Publishing organizations appearing in records: peer_reviewed_research

Thomas A

4 represented evidence records

Years represented: 2015, 2016, 2022, 2024

Publishing organizations appearing in records: peer_reviewed_research

Delahaut P

2 represented evidence records

Years represented: 2015, 2016

Publishing organizations appearing in records: peer_reviewed_research

Fichant E

2 represented evidence records

Years represented: 2015, 2016

Publishing organizations appearing in records: peer_reviewed_research

Frohman LA

4 represented evidence records

Years represented: 2006, 2009

Publishing organizations appearing in records: peer_reviewed_research

Schänzer W

2 represented evidence records

Years represented: 2015, 2016

Publishing organizations appearing in records: peer_reviewed_research

Walpurgis K

2 represented evidence records

Years represented: 2015, 2024

Publishing organizations appearing in records: peer_reviewed_research

Abbate V.

1 represented evidence record

Years represented: 2021

Publishing organizations appearing in records: peer_reviewed_research

Alba M

1 represented evidence record

Years represented: 2006

Publishing organizations appearing in records: peer_reviewed_research

Alechaga É

1 represented evidence record

Years represented: 2020

Publishing organizations appearing in records: peer_reviewed_research

Awan TM.

1 represented evidence record

Years represented: 2026

Publishing organizations appearing in records: peer_reviewed_research

Bailey S

1 represented evidence record

Years represented: 2019

Publishing organizations appearing in records: peer_reviewed_research

Connections

Follow the scientific relationships

Connections appear only when they are represented by the project’s underlying records.

Open 1 represented connection ↓

institution

peer_reviewed_research

represented evidence source

Traceability

Follow the record back to its source

The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.

Source publication state

A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.

Reviewer provenance state

“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.

Domain conclusion → Evidence

Connected

Evidence → Source

Connected

Source → Original record

Connected

Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.

Reconciled for 4 domain conclusions and 0 featured studies.

Detailed study-to-domain mappings and original-source paths appear in the CJC-1295 evidence-governance section.

Inspect the ranked source records

Observational archive

What contributors reported

Observational archive data is intentionally separated from published scientific evidence.

Observational boundary

Insufficient eligible observations are available for display under the current filters.

Insufficient eligible observations are currently represented to display aggregated findings for this peptide.

Regulatory context

Published jurisdictional records

Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.

Research + media

Media connected to this scientific record

Only media explicitly linked through the project’s relationship system appears here.

No scientifically connected media is currently represented for this peptide.

Sources + provenance

Read the scientific record with its boundaries intact

The public record organizes reviewed evidence; it does not establish scientific truth by itself.
Association, mechanism, observation and regulatory status must not be represented as proof of clinical efficacy or safety.
Observational reports describe contributor experiences and cannot establish causation, effectiveness, safety or clinical benefit.
Contradictory and qualifying evidence must remain visible rather than being silently discarded.
Absence of represented evidence is not evidence that research does not exist.
Research gaps identify unresolved questions; they are not negative conclusions.
Regulatory status is distinct from scientific evidence quality.
Media relationships provide context and explanation; they do not increase the strength of scientific evidence.
A section with no represented records is an incomplete project record, not a scientific conclusion.
Researcher and institutional relationships are shown only when supported by represented records and must not be interpreted as rankings or endorsements.

Generated: 11/8/2026, 5:28:52 PM

global evidence atlas

CJC-1295 research, ranked and separated by purpose

This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.

36Discoverable source universe
36Ranked screening records
4Research domains
0Accountably approved conclusions

36 matching records · ranked 2026-09-18

Page 1 of 2

Count reconciliation: 36 discoverable source records match the peptide identity query; 36 are retained in this bounded, ranked screening view; 0 belong to the separate governed layer labeled “Accountably approved conclusions.” Domain totals overlap because one publication may inform several questions.

governance and regulatory context

CJC-1295: what this atlas does and does not establish

Last checked
2026-09-18
Accountable publication approval
Not yet approved by a named accountable reviewer. Machine screening only.

No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.

Regulatory status by jurisdiction

Absence of a record in this pass is not proof that no authorization exists. Status must remain jurisdiction-, product-, formulation-, and date-specific.

  • European Union (EMA)not approvedchecked 2026-09-08

    No centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026.

    European Medicines Agency medicines database
  • United States (FDA)not approvedchecked 2026-09-08

    No FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026.

    Drugs@FDA: FDA-Approved Drugs

25 of 36 screening records carry a machine-proposed evidence-strength grade; the remainder are unassigned pending further review.

CJC-1295 evidence · ranking key

How evidence is ranked

A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.

A

Practice-defining evidence

Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.

B

Strong supporting evidence

Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.

C

Contextual evidence

Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.

D

Signal-generating evidence

Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.

Tier and confidence answer different questions

Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.

Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.

peptide explorer

Structural visualization and provenance

Evidence-class labeling remains visible even when interactive rendering is unavailable. Representative geometry is not an experimentally determined or predicted biological conformation.

Fully specified molecular identity

Molecular formula
C165H269N47O46
Molecular weight
3647.2 g/mol
Exact identity / sequence notation
H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Nε-3-maleimidopropionyl)-NH2
Identity-defining modifications
  • D-Ala2
  • Gln8, Ala15, and Leu27 substitutions
  • Lys30 Nε-3-maleimidopropionyl DAC
  • C-terminal amide
PubChem CID
91971820
InChIKey
ZUQGTWKGESAQCD-ZGFIGYLBSA-N

DAC-bearing molecule; it is not the distinct 29-residue no-DAC analog catalogued as PubChem CID 56841945.

Sources: NIH PubChem — CJC-1295, DAC-bearing · reviewed 2026-09-17

Representative sequence-derived model
Structure source
Generated from this record's governed amino-acid sequence
Identifier
Not applicable — not a database structure
Method
Schematic layout ordered by residue position only; not a molecular-dynamics, homology, or fold prediction
Confidence / limitations
Illustrative only. Not physically accurate; carries no structural, binding-site, or activity meaning.
Provenance
WPF governed PeptideChemistry record
Retrieved / last reviewed
2026-09-17

This is a representative, sequence-derived model ordered by residue position only. It is not the peptide's experimentally determined or predicted biological conformation, and it carries no claim about real bond angles, distances, secondary structure, binding sites, or activity.

Suggested citation

  • APA

    World Peptide Foundation. (n.d.). CJC-1295 — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 8, 2026.) https://www.worldpeptidefoundation.org/directory/cjc-1295

  • AMA / Vancouver

    World Peptide Foundation. CJC-1295 — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 8, 2026. https://www.worldpeptidefoundation.org/directory/cjc-1295